Fresenius Kabi Unveils 2026 Strategy With Focus On Business Not Region
Increased Focus On Biosimilars And Peptides Under New CEO Michael Sen
Fresenius Kabi has revealed a five-year strategic roadmap, driven by its fresh management team, including broadly to increase the injectables specialist’s global competitiveness and advance organizational effectiveness.
